Transformative Therapies for Autoimmune Diseases
LinkedIn
Twitter
Svenska
About
About Cyxone
Management
Board of Directors
Scientific Advisory Board
Therapy Areas
Autoimmune and Autoinflammatory Diseases
Rheumatoid Arthritis
Multiple Sclerosis
Pipeline
Our Projects
Rabeximod
T20K
Intellectual Property
Investors
Investor Relations
Share information
Owners
Financial Reports
Financial Calendar
Share issues
Analysts
Corporate governance
General Meetings
News
News
Press Releases
Cyxone in media
Company Presentations
Events
Interim Report Q3, 2022
Dec 27, 2021
We only use cookies that are necessary for the function of the website. No cookies are used for analysis or marketing purpose.
Accept
Manage consent
Close
Cookies
Vi placerar inga analys- eller marknadsföringscookies utan enbart cookies som är nödvändiga för hemsidans funktion.
